Compare VMD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMD | CRDF |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.2M | 114.2M |
| IPO Year | 2018 | 2012 |
| Metric | VMD | CRDF |
|---|---|---|
| Price | $9.98 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 208.5K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | 27.37 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $270,280,000.00 | $365,993.00 |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | $164.00 | ★ N/A |
| Revenue Growth | 20.52 | ★ 49.61 |
| 52 Week Low | $5.93 | $1.35 |
| 52 Week High | $10.18 | $4.56 |
| Indicator | VMD | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 43.31 |
| Support Level | $9.22 | N/A |
| Resistance Level | $10.05 | $1.76 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 93.53 | 26.00 |
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.